AIM
EVFM

Alambic Investment Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Alambic Investment Management’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-388
Closed -$49K – 539
2015
Q4 		$49K Buy
+388
New +$256K 0.03% 358

Other funds holding EVFM

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Alambic Investment Management's EVFM Position: Q1 2016 in Review

Alambic Investment Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q1 2016, closing a stake of 388 shares — an estimated $49K sold.

Alambic Investment Management first reported a position in EVFM in Q4 2015 and held it in 1 quarter. The position peaked at $49K in Q4 2015. 20 funds tracked by Wall St. Rank hold EVFM as of Q1 2016.

  • Alambic Investment Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Alambic Investment Management sold 388 Evofem Biosciences, Inc. Common Stock shares in Q1 2016, an estimated $49K.
  • Alambic Investment Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2015 and held it in 1 quarter.
  • Alambic Investment Management's Evofem Biosciences, Inc. Common Stock position peaked at $49K in Q4 2015.
  • 20 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q1 2016.

Based on Alambic Investment Management's 13F filing for Q1 2016, filed 5 May 2016.